9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025 Pfizer aims to submit regulatory filings in ...

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Cancer dominates the drug development pipeline, but industry has paid little attention over the years to cancer cachexia — the complex weight-loss syndrome that accounts for 20–30% of cancer deaths.

In a letter to the hemophilia community, Pfizer Inc. reported a death due to cerebellar infarction and subsequent cerebral hemorrhage in a long-term extension trial participant taking the New ...

This trial tested a new treatment for patients with a type of breast cancer (metastatic breast cancer (MBC)) that is positive for HER2, which means the cancer cells have a specific protein that helps ...

(RTTNews) - Pfizer Inc. (PFE) has announced that a participant in the long-term extension trial evaluating Marstacimab in people living with hemophilia A or B with or without inhibitors has passed ...

Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial. The trial ...

Shares of Sarepta Therapeutics Inc. SRPT gained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a late-stage trial. Pfizer Inc. said late Wednesday that its ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...